These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 3045195)

  • 21. Update on peripheral arterial vasodilation, ascites and hepatorenal syndrome in cirrhosis.
    Knotek M; Rogachev B; Schrier RW
    Can J Gastroenterol; 2000 Nov; 14 Suppl D():112D-121D. PubMed ID: 11110623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogenesis of ascites formation and hepatorenal syndrome: humoral and hemodynamic factors.
    Ring-Larsen H; Henriksen JH
    Semin Liver Dis; 1986 Nov; 6(4):341-52. PubMed ID: 3544227
    [No Abstract]   [Full Text] [Related]  

  • 23. Fluid retention in cirrhosis: pathophysiology and management.
    Kashani A; Landaverde C; Medici V; Rossaro L
    QJM; 2008 Feb; 101(2):71-85. PubMed ID: 18184668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hepatorenal syndrome].
    Brzozowski R
    Pol Arch Med Wewn; 1972 Oct; 49(4):357-71. PubMed ID: 4571818
    [No Abstract]   [Full Text] [Related]  

  • 25. [Liver cirrhosis: pathogenesis of ascites and disturbance of renal function].
    Toledo C; Ginés P; Arroyo V
    Rev Med Chil; 1992 Feb; 120(2):180-7. PubMed ID: 1340557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of human albumin for the treatment of ascites in patients with liver cirrhosis: item of safety, facts, controversies and perspectives.
    Facciorusso A; Nacchiero MC; Rosania R; Laonigro G; Longo N; Panella C; Ierardi E
    Curr Drug Saf; 2011 Sep; 6(4):267-74. PubMed ID: 22129322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Influence of circulatory dysfunction on the treatment of ascites and hepatorenal syndrome: vasoconstrictor and diuretic drug treatment].
    Torre A; Terra C; Guevara M; Ginès P
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():8-14. PubMed ID: 15195529
    [No Abstract]   [Full Text] [Related]  

  • 28. Intrarenal resistance index (RI) as a predictor of early renal impairment in patients with liver cirrhosis.
    Goyal S; Dixit VK; Jain AK; Shukla RC; Ghosh J; Kumar V
    Trop Gastroenterol; 2013; 34(4):235-9. PubMed ID: 25046885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ascites and hepatorenal syndrome: pathophysiology and management.
    Roberts LR; Kamath PS
    Mayo Clin Proc; 1996 Sep; 71(9):874-81. PubMed ID: 8790265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation.
    Moreau R
    J Hepatol; 2004 Jan; 40(1):159-61. PubMed ID: 14672628
    [No Abstract]   [Full Text] [Related]  

  • 31. [Physiopathology of nephropathy in liver cirrhosis. Pathogenetic role of ascites and of inferior vena cava pressure increase].
    Gatta A; Zuin R; Merkel C; Milani L; Ruol A
    Minerva Dietol Gastroenterol; 1979; 25(1):9-16. PubMed ID: 450267
    [No Abstract]   [Full Text] [Related]  

  • 32. Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites.
    Umgelter A; Reindl W; Franzen M; Lenhardt C; Huber W; Schmid RM
    Intensive Care Med; 2009 Jan; 35(1):152-6. PubMed ID: 18802688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathophysiology of the hepatorenal syndrome and potential for therapy.
    Levy M
    Am J Cardiol; 1987 Dec; 60(17):66I-72I. PubMed ID: 3687808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem.
    Arroyo V; Jiménez W
    J Hepatol; 2000; 32(1 Suppl):157-70. PubMed ID: 10728802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic nephropathy, related to haemodynamics.
    Ring-Larsen H
    Liver; 1983 Oct; 3(5):265-89. PubMed ID: 6358759
    [No Abstract]   [Full Text] [Related]  

  • 36. [Natural course and physiopathology of ascites in the cirrhotic patient].
    Bernardi M; Colantoni A; Caraceni P; Sica G; Trevisani F
    Ann Ital Med Int; 1996 Oct; 11 Suppl 2():30S-38S. PubMed ID: 9004818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Endogenous digitalis-like factor in liver cirrhosis and cholestasis].
    Behrens R; Glauck D; Kaltenborn G; Behrens B; Wache H; Schlee H; Rink C; Böhme I; Nilius R
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():20-3. PubMed ID: 7483706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of ascites and hepatorenal syndrome.
    Piano S; Tonon M; Angeli P
    Hepatol Int; 2018 Feb; 12(Suppl 1):122-134. PubMed ID: 28836115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.
    Karwa R; Woodis CB
    Ann Pharmacother; 2009 Apr; 43(4):692-9. PubMed ID: 19299324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ascites: pathophysiology and management.
    Wyllie R; Arasu TS; Fitzgerald JF
    J Pediatr; 1980 Aug; 97(2):167-76. PubMed ID: 7400881
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.